InMed Pharmaceuticals News | Press Releases

Skip to content

Facebook Twitter Linkedin

Pharmaceutical
Manufacturing
Investors
Corporate
Learn

Menu

Pharmaceutical
Manufacturing
Investors
Corporate
Learn

Press Releases

InMed Pharmaceuticals Added to CSE25 Index

September 21, 2017

InMed Retains Consultant Ben Paterson for Biosynthesis Development

September 19, 2017

InMed Files Provisional Patent for Biosynthesis of Cannabinoids

September 12, 2017

InMed Announces Appointment of Creative Capital Media

August 18, 2017

InMed Announces Publication in European Journal of Pain

July 27, 2017

InMed Signs R&D Agreement with ATERA

July 10, 2017

InMed Announces Agreement to Advance a Topical Formulation of INM-750

June 13, 2017

InMed Raises $5.75 Million Through Underwritten Financing Including Full Exercise of the Over-Allotment Option

May 31, 2017

InMed Announces Pricing of $5,004,000 Underwritten Financing

May 23, 2017

InMed Pharmaceuticals Files Provisional Patent Application for Ophthalmic Drug Delivery

May 10, 2017

InMed Pharmaceuticals Announces Marketed Offering of Common Shares

April 21, 2017

InMed Pharmaceuticals Shareholders Approve New Stock Option Plan and Articles

March 24, 2017

InMed Pharmaceuticals to Present at the 29th Annual ROTH Conference

March 8, 2017

InMed Pharmaceuticals Files PCT Patent for Epidermolysis Bullosa Simplex

March 2, 2017

InMed Receives over $1,350,000 From Warrant Exercise

February 27, 2017

InMed Pharmaceuticals to Present at the 2017 BIO CEO & Investor Conference

February 9, 2017

InMed Pharmaceuticals, Inc. Closes Non-Brokered Private Placement for C$1,500,000

January 18, 2017

InMed Pharmaceuticals Appoints Martin Bott to Board of Directors

January 13, 2017

InMed Pharmaceuticals, Inc. Announces Non-Brokered Private Placement of C$1,000,000

January 9, 2017

InMed Launches New Website

January 9, 2017

« Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Next »

Management

Board of Directors

Scientific Advisory Board

Investor Alerts

Sign up to receive news releases from InMed Pharmaceuticals.

#310 – 815 West Hastings St.
Vancouver, BC, Canada
V6C 1B4

Pharmaceutical

Cannabinoids in Development
INM-755 for Epidermolysis Bullosa
INM-088 for Glaucoma
INM-900 Series for Neurodegenerative Disease
Novel Cannabinoid Analogs

MANUFACTURING

BayMedica – Rare Cannabinoid Ingredients
Cannabinoid Manufacturing Expertise
IntegraSyn™ Cannabinoid Manufacturing

Investor

News
Events
Stock Information
Corporate Governance
Financials & AGM Materials
Filings
Presentations
Media & Videos
Investor Contact

CORPORATE

Management
Board of Directors
Scientific Advisors
Partners and Collaborators
Careers
Contact

Learn

What is Cannabinol (CBN)?
What is Epidermolysis Bullosa (EB)?
What is Glaucoma?
Cannabinoid Manufacturing Economics 101
GMP Manufacturing Standards by Product Type
Cannabinoids for Glaucoma
Cannabinoid Science
Articles and Videos

© Copyright 2023 InMed Pharmaceuticals Inc.

Privacy Policy
Terms of Use
Legal Disclaimer

Find Us On:

Sign up to receive emails from InMed Pharmaceuticals

"*" indicates required fields

Name*

First name* Last name*

Email*

Consent*

By providing your e-mail address, you consent to receive news, press releases, quarterly and annual reports, presentations and other information from InMed Pharmaceuticals Inc. You can unsubscribe at any time.

CAPTCHA